Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

INTRODUCTION: Once-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2 mg in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansen, Pierre, Chubb, Barrie, Hunt, Barnaby, Malkin, Samuel J. P., Sandberg, Anna, Capehorn, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467468/
https://www.ncbi.nlm.nih.gov/pubmed/32306244
http://dx.doi.org/10.1007/s12325-020-01337-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467468/
https://www.ncbi.nlm.nih.gov/pubmed/32306244
http://dx.doi.org/10.1007/s12325-020-01337-7

Ejemplares similares